key: cord-0075760-3m4bj3w7 authors: Falavigna, Maicon; Belli, Karlyse Claudino; Barbosa, Alexandre Naime; Zavascki, Alexandre Prehn; Nastri, Ana Catharina de Seixas Santos; Santana, Christiane Machado; Stein, Cinara; Gräf, Débora Dalmas; Cadegiani, Flavio Adsuara; Guimarães, Hélio Penna; Monteiro, José Tadeu; Ferreira, Juliana Carvalho; de Azevedo, Luciano Cesar Pontes; Magri, Marcelo Mihailenko Chaves; Sobreira, Marcone Lima; Dias, Maria Beatriz Gandra de Souza; de Oliveira, Maura Salaroli; Corradi, Mirian de Freitas Dal Ben; Rosa, Regis; Heinzelmann, Ricardo Souza; da Silva, Rosemeri Maurici; Junior, Rubens Belfort; Cimerman, Sergio; Colpani, Verônica; Veiga, Viviane Cordeiro; de Carvalho, Carlos Roberto Ribeiro title: Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT). date: 2022-03-17 journal: Braz J Infect Dis DOI: 10.1016/j.bjid.2022.102347 sha: d71807afdef1da103ae525d2648e0c663dd9304b doc_id: 75760 cord_uid: 3m4bj3w7 BACKGROUND: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil. METHODS: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method. RESULTS: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation. CONCLUSION: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments. Worldwide, as of February 20 th , 2022, the World Health Organization (WHO) had reported over 422 million confirmed cases and over 5.8 million deaths from COVID-19. [1] In Brazil, as of February 24 th , 2022, 28,484,890 cases and 646,419 deaths from COVID-19 had been confirmed, with an estimated cumulative incidence rate of 13,554.7 cases per 100,000 population and a cumulative mortality rate of 307,6 deaths per 100,000 population. [2] Most frequently, people with COVID-19 have mild clinical manifestations, developing symptoms such as fever, dry cough, and fatigue, with self-limited resolution. However, approximately 14% of COVID-19 cases progress to severe disease and may require oxygen therapy or hospitalization, and 5% are admitted to an Intensive Care Unit (ICU). [1] Given the high morbidity and mortality from COVID-19 in a short period, health care systems all around the world face the challenge of reorganizing to meet the demands imposed by the pandemic. Also, there are uncertainties and variations in clinical practice, [3] and scientific knowledge is not able to evolve at the pace required by health care needs. Therefore, healthcare services and health professionals are needed to ensure that patients are cared for in a timely manner, leading to the achievement of better clinical outcomes. Given the continued importance of COVID-19 and the need for adequate prehospital management, this document aims to guide clinical practice regarding the pharmacological treatment of outpatients with COVID-19. The method used in this document was rapid guideline development, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). [5, 6] Organization, panel composition, and guideline development From late June to October 2021, the Steering Committee held 10 online video conferences with the experts to prepare and discuss the guidelines, until a consensus was achieved. The Steering Committee members and methodologists did not interfere in the development of guidelines by the experts. To identify the clinical questions of interest, the technologies evaluated in nine national and international guidelines for the treatment of outpatients with suspected or confirmed COVID-19 were reviewed. The most relevant technologies with greatest practice variation in Brazil were selected, provided they had regulatory approval for outpatient use. In addition to those documents, a position statement issued by the Pan American Health Organization (PAHO) was considered in the discussions. The following technologies were evaluated: anticoagulants, azithromycin, monoclonal antibodies, budesonide, colchicine, chloroquine and hydroxychloroquine, systemic corticosteroids, ivermectin, nitazoxanide, and convalescent plasma. Recommendations, evidence profiles, and GRADE (Grading of Recommendations Assessment, Development and Evaluation) domains were extracted from evidence-to-decision tables through the eCovid RecMap platform, and the original documents were consulted whenever necessary. [7] The identified guidelines were reviewed, and their recommendations were extracted. The following guidelines and evidence synthesis documents were used in the guideline development process: Knowledge about COVID-19 has evolved over the past 12 months as a result of collaborative efforts from several countries and research groups, with the development of randomized clinical trials evaluating potential drugs for disease treatment. Therefore, the guideline panel obtained evidence exclusively from randomized clinical trials, which are deemed the most robust and adequate studies to ascertain drug efficacy and safety. Thus, the PubMed and medRxiv databases were searched to identify randomized clinical trials evaluating the use of each of the technologies for outpatient treatment. A detailed description of the methodology (including search strategy, screening and study selection, data collection and analysis, risk of bias and certainty of evidence), recommendations from international guidelines, evidence synthesis, and additional rationale for the judgment made are presented in supplementary material. For developing recommendations, evidence of benefits and risks, quality of evidence, costs and use of resources, feasibility, and aspects related to equity, patient values and preferences, and acceptability were considered. The GRADE system was used to assess certainty in evidence, which is rated into four levels: high, moderate, low, and very low (Table 1) . For each recommendation, the direction of the course of action was discussed (whether to perform or not the proposed action), and the strength of recommendation was defined as strong or conditional according to the GRADE system ( Table 2 ). Supplementary material shows evidence profile tables with the certainty of evidence and the strength of recommendation, together with the corresponding interpretation, for each of the evaluated technologies. [18, 19] The terminology "we recommend" and "we suggest" denote different degrees of emphasis on the strength of recommendation, as shown below: "We recommend" represents a strong recommendation, which should be incorporated as a routine practice, either for or against the use of a given intervention; "We suggest" represents a conditional recommendation, which is applicable to most situations; however, either due to lack of robust evidence or to expected variation in treatment effectiveness, other approaches may be justifiable. These Brazilian guidelines address adult male and female patients with suspected or confirmed diagnosis of SARS-CoV-2 infection. These guidelines do not cover specific recommendations for pregnant women. Ten recommendations were made. The recommendations are summarized in Table 3 and in Figure 1 . Below we present the recommendations, the rationale for decision-making, and, when relevant, considerations for implementation. Detailed information on the evidence supporting each recommendation is shown in supplementary material. Recommendation 1: We suggest against using anticoagulants in outpatients with suspected or confirmed COVID-19 (conditional recommendation, very low certainty in evidence). Rationale for recommendation: The panel concluded that there is uncertainty about the benefit of using anticoagulants in patients with suspected or confirmed COVID-19 undergoing outpatient treatment; additionally, anticoagulation is associated with an increased risk of bleeding events, which can be even more challenging in an outpatient setting, where closer monitoring to minimize anticoagulation risks is sometimes unfeasible. Also, the only randomized study identified evaluated sulodexide, a drug not available in Brazil, thus being used as indirect evidence for other drugs. Therefore, we understand that there is no basis for indicating routine anticoagulation therapy at this time, and this recommendation should be revised after publication of phase 3 studies, such as the PREVENT-HD evaluating rivaroxaban, and the ACTIV4-outpatients and the APOLLO evaluating apixaban. [20] [21] [22] Rationale for recommendation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use in patients with suspected or confirmed COVID-19 undergoing outpatient treatment. The studies available to date are all open label, with benefit being demonstrated for subjective outcomes. Also, studies generally evaluated patients at higher risk, with no evidence for low-risk patients (young and without comorbidities). Thus, a conditional recommendation against the use of budesonide is presented. General considerations for implementation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use in outpatients with COVID-19. The clinical trials available to date are all open label, with benefit being demonstrated for subjective outcomes. Also, studies generally evaluated patients at higher risk, with no evidence for low-risk patients (young and without comorbidities); patients with other clinical indications for budesonide (e.g., asthma) benefit from its initiation or maintenance. Recommendation 5: We suggest against using colchicine in outpatients with suspected or confirmed COVID-19 (conditional recommendation, low certainty in evidence). Rationale for recommendation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use. General considerations for implementation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use. Recommendation 6: We recommend against using corticosteroids in outpatients with suspected or Rationale for recommendation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use. General considerations for implementation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use. Recommendation 9: We suggest against using nitazoxanide in outpatients with suspected or confirmed COVID-19 (conditional recommendation, very low certainty in evidence). Rationale for recommendation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use. General considerations for implementation: The panel concluded that, although benefit cannot be ruled out and the drug is relatively safe, current evidence is insufficient to indicate its routine use. Recommendation 10: We suggest against using convalescent plasma in outpatients with suspected or confirmed COVID-19 (conditional recommendation, moderate certainty in evidence). Rationale for recommendation: The panel concluded that there is insufficient evidence to indicate the use of convalescent plasma currently, with studies showing divergent results. General considerations for implementation: There are still uncertainty about evidence regarding specific, high-risk populations, such as immunosuppressed and transplanted patients. The recommendations made in this guideline were based on evidence from previous rapid guidelines and systematic reviews, carefully evaluated by an expert panel (9 Brazilian Ministry of Health representatives, 23 clinical experts, and 5 methodologists) using the GRADE-ADOLOPMENT methodology for judging and drafting recommendations. [5, 6, 23] Thus, 10 recommendations were prepared, and most of them advise against the use of the evaluated technologies. The expert panel's decision to contraindicate the use of these drugs is consistent with the findings of international guidelines, which also contraindicate clinical treatment for COVID-19 with anticoagulants, [10, 14] azithromycin, [10, 13, 14] budesonide, [10] colchicine, [10, 13] corticosteroids, [10, [13] [14] [15] hydroxychloroquine/chloroquine alone or combined with azithromycin, [10, 11, 14, 15] ivermectin, [10, 12, 15] nitazoxanide, [10] or convalescent plasma. [10, 12, 14] Additionally, there are two guidelines developed in Brazil that also contraindicate the use of some of these drugs. [8, 24] In epidemic situations when no clinical treatment with consolidated effectiveness is available, . [32] More recently, preliminary data regarding the use of nirmatrelvir/ritonavir showed an 80% reduction in hospitalizations. [33] Fluvoxamine is a selective serotonin reuptake inhibitor indicated for treating depression, obsessive-compulsive disorders, and other health conditions. [34] A recent study demonstrated the benefit of fluvoxamine in reducing the need for hospitalization, defined as either retention for more than six hours in an emergency setting or transfer to a tertiary hospital in patients at high risk of developing severe COVID-19. [35] Tixagevimab+cilgavimab consists of a combination of monoclonal antibodies, probably with similar effectiveness, and has the advantage of being delivered by a intramuscular injection. [36] These guidelines covered only recommendations for outpatients with COVID-19. In the Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19 [4] we provided 16 recommendations related to 12 drugs. In those guidelines we recommended the use of corticosteroids (preferentially dexamethasone) for patients using supplemental oxygen. Also, suggested the use heparin or enoxaparin in therapeutic doses in noncritical patients (those with no need for vasoactive drugs, renal replacement therapy, high-flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation) hospitalized with COVID-19. In addition, we acknowledge the benefit of tocilizumab for patients using noninvasive ventilation or high-flow nasal cannula; however, it is not possible to recommend it, as this use is off label and there are uncertainties regarding access to the drug that affect the ability to meet the potential demand. Although remdesivir has potential clinical benefit in this population, its costs and uncertainty related to its effectiveness resulted in a suggestion against its routine use. The effectiveness of most therapies in the treatment of COVID-19 in hospitalized patients was not proved; thus, azithromycin, antimicrobials, casirivimab plus imdevimab, chloroquine or hydroxychloroquine, colchicine, convalescent plasma, ivermectin, lopinavir/ritonavir, and remdesivir were not recommended in those guidelines. [4] Some other interventions may be effective in hospitalized patients with COVID-19. Tofacitinib in a phase II randomized study showed 37% reduction on the risk of death or respiratory failure. [37] Baricitinib reduced 38% the risk of mortality compared to placebo. [38] Demonstrating the technologies that should not be used in clinical practice is also of great importance for patient care, particularly in the context of COVID-19, as clinicians worldwide have used technologies without proven effectiveness, especially in the early stages of the pandemic. [11] Thus, the objectives of this guideline were to improve the quality of patient care and to help standardize care in different health care settings and systems that serve patients who are at home or who attend outpatient clinics. With this guideline, we expect to guide the care of outpatients with COVID-19 in Brazil, highlighting the existing uncertainties, especially regarding the ineffectiveness or lack of documented benefit of most of the evaluated drugs. In addition to the evidence available in the scientific literature, the recommendations considered aspects relevant to the Brazilian context, such as the availability of drugs, the acceptability of interventions by the population and by clinicians, and the associated costs. Furthermore, most of the recommendations are currently in line with the therapeutic approaches recommended by the main international organizations and societies, such as the WHO, the NIH, and the IDSA. [1, 10, 12, 24] This document is a position statement supported by seven medical societies and was developed considering the need for comprehensive recommendations and the perspective of different medical specialties, given the weakness of available evidence and the relevance that should be given to the topic. Importantly, because of the large number of emerging therapies for COVID-19, these recommendations may need to be updated as new evidence appears, in particular randomized clinical trials of high methodological quality and new position statements issued by international societies and organizations. The authors declare no conflicts of interest. The methodological coordination for the development of these guidelines was funded by the Institutional Development Program of the Brazilian Unified Health System (PROADI-SUS) together with Hospital Moinhos de Vento. There is strong confidence that the true effect is close to the estimate. It is unlikely that additional work will modify the confidence in the effect estimate. Moderate There is moderate confidence in the estimated effect. Future work may change the confidence in the effect estimate and may even change the estimate. Confidence in the effect is limited. Future work is likely to have a major impact on the confidence in the effect estimate. Very low Confidence in the effect estimate is very limited. Any effect estimate is uncertain. There is an important degree of uncertainty in the findings. Weekly epidemiological update on COVID-19 -22 International variation in the management of severe COVID-19 patients Diretrizes Brasileiras para Tratamento Hospitalar do Paciente com COVID-19 -Capítulo 2: Tratamento Farmacológico Developing trustworthy recommendations as part of an urgent response (1-2 weeks): a GRADE concept paper GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia COVID-19: Summary Recommendations -Brazilian Medical Association (AMB) National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19 Supporting Australia's healthcare professionals with continually updated evidence-based clinical guidelines Management of hospitalised adults with Coronavirus Disease-19 (COVID-19): A European Respiratory Society living guideline IDSA guidelines on the treatment and management of patients with COVID-19 National Institute for Health and Care Excellence -NICE. COVID-19 rapid guideline: managing COVID-19 World Health Organization -WHO. Therapeutics and COVID-19 Ongoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence Recommendations for use of topical inhalant budesonide in COVID-19: A Position Paper of the German Society for Applied Allergology (AeDA) and the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO) Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise Introduction-GRADE evidence profiles and summary of findings tables A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 (APOLLO) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics Who COVID-19 Solidarity Therapeutics Trial Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study Fluvoxamine for outpatients with COVID-19: where do we stand? Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the Together randomised, platform clinical trial AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 STOP-COVID Trial Investigators. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group Figure 1. Recommendations for drug treatment of outpatients with COVID-19. Source: the authors We are grateful for all the support and endorsement of the Brazilian Association of Emergency Anticoagulants Recommendation 1: We suggest against using anticoagulants in outpatients with suspected or confirmed COVID-19(conditional recommendation, very low certainty in evidence). Recommendation 2: We recommend against using azithromycin in outpatients with suspected or confirmed COVID-19 (strong recommendation, moderate certainty in evidence). Source: The authors.